Thursday, November 10, 6:30am - 7:50am (EST)
Your search did not return any results.
Following WHO Guidelines to implement the BPaL regimen (bedaquiline, pretomanid and linezolid) under operations research (OR) conditions in June 2020, several countries began implementing the regimen and scaling up access. As a three-drug, all-oral, 6-month treatment, the BPaL regimen simplifies therapy compared to the longer 18-month, 7–9 drug treatments for pre-extensively drug-resistant TB. Implementing BPaL required countries to prepare and execute plans deliberately and systematically. The first OR commenced within 5 months of the WHO guidelines, with several others following shortly thereafter. There are currently more than 12 ORs underway and three countries have developed sufficient experience to begin scaling up the BPaL regimen under OR conditions. Additionally, since 2019, a vast majority of DR-TB caseload in the United States has been treated with BPaL following US FDA approval.
Symposium participants will learn from implementation experience of early BPaL adopters about best practices for rapidly and effectively deploying novel DR-TB regimens. Please see the online program for additional details: https://unionconf2022.abstractserver.com/planner/#/preview/session/3dfaee5ef9177115f